{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T04:46:36Z","timestamp":1785732396724,"version":"3.56.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the clinical outcomes associated with piperacillin-tazobactam (PIP-TAZ) versus cefotaxime-tazobactam (CTX-TAZ) in elderly patients with lower respiratory tract infection (LRTI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 92 elderly patients with respiratory tract infection from March 2024 to April 2025 were selected as the subjects and divided into two groups of 46 cases in each group according to different treatment drugs. The control group was treated with tazobactam sodium\/cefotaxime sodium, and the observation group was treated with piperacillin sodium for injection. The effects of the two groups were evaluated after 2 weeks of treatment. The blood gas level, inflammatory factors, lung function and drug safety were compared between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Both groups showed significant improvements in arterial blood gases after treatment. Patients receiving PIP-TAZ exhibited a significantly greater increase in PaO2 and a greater reduction in PaCO2 compared to those receiving CTX-TAZ (both\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). Inflammatory markers (PCT, WBC, CRP) decreased, and pulmonary function indices (PEF, FVC, FEV1) increased significantly in both groups, with numerically greater improvements in the PIP-TAZ group (all\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05, unadjusted). There was no statistical difference in drug safety between the two groups (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;gt; 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this comparative study, both piperacillin-tazobactam and cefotaxime-tazobactam demonstrated clinical effectiveness in improving objective physiological and inflammatory parameters in elderly patients with LRTIs. In this non-randomized comparison, the piperacillin-tazobactam regimen was associated with statistically significant, but unadjusted, differences favoring greater improvements in arterial blood gases (PaO2 and PaCO2), reductions in inflammatory biomarkers (PCT, WBC, CRP), and enhancements in lung function indices (PEF, FVC, FEV1) after 2\u00a0weeks of treatment compared to the cefotaxime-tazobactam regimen. These observed differences should be considered exploratory. Both treatments exhibited a comparable and acceptable safety profile in this cohort. However, these findings should be interpreted in light of the study\u2019s non-randomized design, heterogeneous infection types, and the inherent differences between the antibiotic regimens. Further large-scale, randomized controlled trials with microbiological confirmation are warranted to validate these observations and define the optimal empiric antibiotic strategy in this vulnerable population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1757937","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T04:27:53Z","timestamp":1785731273000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative significance of piperacillin-tazobactam and cefotaxime-tazobactam in the treatment of respiratory tract infections in the elderly"],"prefix":"10.3389","volume":"17","author":[{"given":"Mengzhe","family":"Peng","sequence":"first","affiliation":[{"name":"School of Pharmacy, Guangdong Medical University","place":["Zhanjiang, Guangdong, China"]},{"name":"Department of Pharmacy, Zhongshan City People\u2019s Hospital","place":["Zhongshan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henian","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhongshan City People\u2019s Hospital","place":["Zhongshan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhongshan City People\u2019s Hospital","place":["Zhongshan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhongshan City People\u2019s Hospital","place":["Zhongshan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyun","family":"Qin","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Guangdong Medical University","place":["Zhanjiang, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"B2","doi-asserted-by":"publisher","first-page":"e38904","DOI":"10.1097\/MD.0000000000038904","article-title":"Effectiveness of bairui granules in the treatment of respiratory tract infections: a systematic review and meta-analysis","volume":"103","author":"Chai","year":"2024","journal-title":"Medicine (Baltimore)."},{"key":"B4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.19803\/j.1672-8629.20220570","article-title":"Analysis of reports of drug-induced anaphylactic shock in chongqing from 2015 to 2020","volume":"20","author":"Chen","year":"2023","journal-title":"Chin. J. Pharmacovigil."},{"key":"B5","doi-asserted-by":"publisher","first-page":"959","DOI":"10.12290\/xhyxzz.2023-0338","article-title":"Expert consensus on clinical application of nucleic acid detection technology for pathogen diagnosis of respiratory tract infections in adults (2023)","volume":"14","year":"2023","journal-title":"J. Peking Union Med. Coll."},{"key":"B6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/CEOR.S55265","article-title":"Antibiotic expected effectiveness and cost under real life microbiology: evaluation of ertapenem and ceftriaxone in the treatment of community-acquired pneumonia for elderly patients in Spain","volume":"6","author":"Grau","year":"2014","journal-title":"Clin. Outcomes Res."},{"key":"B1","doi-asserted-by":"publisher","first-page":"841","DOI":"10.11816\/cn.ni.2024-231044","article-title":"Efficacy and safety of cefoperazone-sulbactam and piperacillin-tazobactam in treatment of complicated urinary tract infection","volume":"34","author":"Ji","year":"2024","journal-title":"Chin. J. Nosocomiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3760\/cma.j.cn101070-20241028-00694","article-title":"Efficacy and safety of aerosol inhaled recombinant human interferon \u03b11b in the treatment of respiratory syncytial virus lower respiratory tract infection in children: a multicenter, randomized, double-blind, placebo-controlled phase III clinical study","volume":"40","author":"Liu","year":"","journal-title":"Chin. J. Pract. Pediatr."},{"key":"B8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3969\/j.issn.1000-484X.2025.01.036","article-title":"Research progress on immune regulation and clinical treatment strategies in respiratory virus infection","volume":"41","author":"Liu","year":"","journal-title":"Chin. J. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00431-023-05401-6","article-title":"Clinical recommendations for the inpatient management of lower respiratory tract infections in children and adolescents with severe neurological impairment in Germany","volume":"183","author":"Mauritz","year":"2024","journal-title":"Eur. J. Pediatr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1111\/all.15997","article-title":"A systematic review and meta-analysis on nutritional and dietary interventions for the treatment of acute respiratory infection in pediatric patients: an EAACI taskforce","volume":"79","author":"Milani","year":"2024","journal-title":"Allergy"},{"key":"B14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3760\/cma.j.issn.1674-2397.2024.05.005","article-title":"Pay attention to the clinical rational application of polymyxin aerosol inhalation in the treatment of multidrug-resistant Gram-negative lower respiratory tract infections","volume":"17","author":"Shi","year":"2024","journal-title":"Chin. J. Clin. Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.13193\/j.issn.1673-7717.2023.12.048","article-title":"Pediatric branch of the Chinese association of traditional Chinese medicine. Expert consensus on the clinical application of xiaoer resuqing oral liquid in the treatment of upper respiratory tract infections in children","volume":"41","author":"Wang","year":"2023","journal-title":"Chin. J. Traditional Chin. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"448","DOI":"10.14053\/j.cnki.ppcr.202305012","article-title":"Physical compatibility of amifostine with 17 intravenous drugs in a simulated Y-type infusion pathway","volume":"26","author":"Wang","year":"2023","journal-title":"Pract. Drugs Clin."},{"key":"B15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3969\/j.issn.1005-3697.2024.06.030","article-title":"Study on the efficacy of piperacillin -tazobactam sodium and cefoperazone -sulbactam sodium in the treatment of severe pneumonia in the elderly","volume":"39","author":"Wang","year":"2024","journal-title":"J. North Sichuan Med. Coll."},{"key":"B16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.13350\/j.cjpb.250113","article-title":"Distribution of pathogens in hospital bloodstream infection and the value of MALDI-TOFMS in rapid identification of pathogens","volume":"20","author":"Xiao","year":"2025","journal-title":"Chin. J. Pathogenic Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"478","DOI":"10.12183\/j.scjpm.2024.05097","article-title":"Pathogen characteristics and drug resistance status of patients in respiratory medicine","volume":"50","author":"Zhang","year":"2024","journal-title":"South China J. Prev. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.20047\/j.issn1673-7210.2024.14.22","article-title":"Clinical study on baoerning oral liquid combined with auricular acupoint therapy for the treatment of lung and spleen qi deficiency syndrome in children with recurrent respiratory tract infection","volume":"21","author":"Zhao","year":"2024","journal-title":"China Med. Her."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1757937\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T04:28:05Z","timestamp":1785731285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1757937\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":17,"alternative-id":["10.3389\/fphar.2026.1757937"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1757937","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"article-number":"1757937"}}